Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone in obsessional compulsive disorder. A prospective case study

B T Farid1, M Bulto

  • 1Department of Psychiatry, New Cross Hospital, Wolverhampton, U.K.

Pharmacopsychiatry
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of a brief behavioral skills intervention to prevent HIV infection among chronic mentally ill adults.

Psychiatric services (Washington, D.C.)·1995
Same author

Occupational risk factors in patients with alcoholic or non-alcoholic liver disease.

Alcohol and alcoholism (Oxford, Oxfordshire)·1994
Same author

Factors associated with risk for HIV infection among chronic mentally ill adults.

The American journal of psychiatry·1994
Same author

Munchausen's syndrome presenting as cystic fibrosis with hemoptysis.

Pediatric pulmonology·1993
Same author

Postviral syndrome.

Journal of the Royal Society of Medicine·1990
Same author

Benzodiazepine prescribing.

Lancet (London, England)·1989
Same journal

Editorial.

Pharmacopsychiatry·2026
Same journal

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
See all related articles

This case study shows Buspirone effectively treated severe obsessive-compulsive disorder (OCD) in a patient resistant to other therapies. The anxiolytic medication significantly reduced the patient's debilitating OCD symptoms.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
  • Treatment-resistant OCD poses significant challenges in clinical practice.
  • Existing therapeutic options, including psychosurgery, may not be effective for all patients.

Observation:

  • A longitudinal case study was conducted on an individual with severe OCD.
  • The patient had previously shown no response to a comprehensive range of treatments.
  • This included interventions up to and including psychosurgery.

Findings:

  • The patient exhibited a notable positive response to the anxiolytic medication Buspirone.
  • The treatment was administered at the recommended dosage.

Related Experiment Videos

  • Buspirone demonstrated a significant effect in reducing the severity of the patient's obsessive-compulsive symptoms.

    • Implications:

    • Buspirone may represent a viable therapeutic option for specific cases of treatment-resistant OCD.
    • Further research into anxiolytics for severe OCD is warranted.
    • This finding could inform treatment strategies for patients with limited therapeutic success.